Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
We Can Medicines Co's revenue for the
three
months ended in Mar. 2026 was NT$797 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was NT$3,221 Mil.
We Can Medicines Co's Revenue per Share for the
three
months ended in Mar. 2026 was NT$17.41.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was NT$71.39.
Warning Sign:
We Can Medicines Co Ltd revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of We Can Medicines Co was -4.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -3.30% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -1.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 6 years, We Can Medicines Co's highest 3-Year average Revenue per Share Growth Rate was 2.50% per year. The lowest was -3.80% per year. And the median was -3.30% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
We Can Medicines Co Revenue Related Terms
We Can Medicines Co Revenue Historical Data
* Premium members only.
The historical data trend for We Can Medicines Co's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Packaged Foods subindustry, We Can Medicines Co's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
We Can Medicines Co Revenue vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, We Can Medicines Co's Revenue distribution charts can be found below:
* The bar in red indicates where We Can Medicines Co's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$3,221 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
We Can Medicines Co (ROCO:6929) has a Revenue of NT$3,221 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on We Can Medicines Co and its competitors.
Is We Can Medicines Co's Revenue too high?
We Can Medicines Co's current Revenue is NT$3,221 Mil. Overall, We Can Medicines Co has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does We Can Medicines Co's Revenue compare to KHC and GIS?
We Can Medicines Co's Revenue of NT$3,221 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Consumer Packaged Goods company?
A good Revenue depends on the Consumer Packaged Goods industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on We Can Medicines Co and its competitors. We Can Medicines Co's current Revenue is NT$3,221 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is We Can Medicines Co stock overvalued right now?
Based on GuruFocus' analysis, We Can Medicines Co (ROCO:6929) is currently considered Possible Value Trap. The stock's GF Value™ is NT$39.07, compared to a current price of NT$22.45 — trading 42.5% below its estimated fair value. The current Revenue is NT$3,221 Mil. We Can Medicines Co's overall GF Score™ is 47/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For We Can Medicines Co (ROCO:6929), the current Revenue is NT$3,221 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is We Can Medicines Co (ROCO:6929) Overvalued in 2026?
Based on GuruFocus' analysis, We Can Medicines Co stock appears to be undervalued.
The current stock price of NT$22.45 is trading 42.5% below its estimated GF Value™ of NT$39.07.
GuruFocus considers We Can Medicines Co to be Possible Value Trap.
Key valuation signals for ROCO:6929:
Revenue: NT$3,221 Mil
GF Value™: NT$39.07 vs. price of NT$22.45 (42.5% below fair value)
No single metric tells the full story. See the ROCO:6929 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
We Can Medicines Co Ltd is a Taiwan-based company mainly engaged in the operation of chain cosmeceutical drugstores. The Company's main products include pharmaceuticals and health food, maternity and infant products, medical supplies, beauty cosmetics, and daily necessities.
47GF Score
Get the complete analysis for ROCO:6929
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6929 has been successfully added to your 
